Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OCRELIZUMAB Cause Upper respiratory tract infection? 594 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 594 reports of Upper respiratory tract infection have been filed in association with OCRELIZUMAB (OCREVUS). This represents 1.1% of all adverse event reports for OCRELIZUMAB.

594
Reports of Upper respiratory tract infection with OCRELIZUMAB
1.1%
of all OCRELIZUMAB reports
7
Deaths
116
Hospitalizations

How Dangerous Is Upper respiratory tract infection From OCRELIZUMAB?

Of the 594 reports, 7 (1.2%) resulted in death, 116 (19.5%) required hospitalization, and 7 (1.2%) were considered life-threatening.

Is Upper respiratory tract infection Listed in the Official Label?

Yes, Upper respiratory tract infection is listed as a known adverse reaction in the official FDA drug label for OCRELIZUMAB.

What Other Side Effects Does OCRELIZUMAB Cause?

Covid-19 (11,454) Fatigue (5,704) Urinary tract infection (3,618) Headache (3,036) Multiple sclerosis (2,609) Asthenia (2,509) Nasopharyngitis (2,479) Gait disturbance (2,384) Pneumonia (2,333) Pain (2,327)

What Other Drugs Cause Upper respiratory tract infection?

ADALIMUMAB (3,306) ETANERCEPT (2,948) TOFACITINIB (1,805) RITUXIMAB (1,713) ABATACEPT (1,623) METHOTREXATE (1,576) TOCILIZUMAB (1,455) APREMILAST (1,437) PREDNISONE (1,354) SECUKINUMAB (1,339)

Which OCRELIZUMAB Alternatives Have Lower Upper respiratory tract infection Risk?

OCRELIZUMAB vs OCRIPLASMIN OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE OCRELIZUMAB vs OCTREOTIDE OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE

Related Pages

OCRELIZUMAB Full Profile All Upper respiratory tract infection Reports All Drugs Causing Upper respiratory tract infection OCRELIZUMAB Demographics